<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A wide variety of beneficial effects have been attributed to <z:chebi fb="0" ids="3962">curcumin</z:chebi>, a major <z:chebi fb="0" ids="26195">polyphenol</z:chebi> from the golden spice Curcuma longa known as turmeric, including amelioration of severe complications of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> such as <z:hpo ids='HP_0001395'>hepatic fibrosis</z:hpo>, <z:hpo ids='HP_0000488'>retinopathy</z:hpo>, <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> and <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present issue of BJP, Lin and colleagues reveal new mechanisms by which <z:chebi fb="0" ids="3962">curcumin</z:chebi> inhibits the activation of hepatic stellate cells in vitro, a hallmark of <z:e sem="disease" ids="C0400966" disease_type="Disease or Syndrome" abbrv="">non-alcoholic steatohepatitis</z:e> and hepatic fibrogenesis associated with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>They demonstrated that <z:chebi fb="0" ids="3962">curcumin</z:chebi> suppresses the advanced glycation end-products (AGEs)-mediated induction of the receptor for AGEs (RAGE) gene expression by increasing PPARγ activity and stimulating de novo synthesis of <z:chebi fb="0" ids="16856">glutathione</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>As a result, downstream elements of RAGE-activated pathways are inhibited, which prevents <z:mp ids='MP_0003674'>oxidative stress</z:mp>, <z:mp ids='MP_0001845'>inflammation</z:mp> and hepatic stellate cell activation </plain></SENT>
<SENT sid="4" pm="."><plain>This report suggests that <z:chebi fb="0" ids="3962">curcumin</z:chebi> may have potential as an anti-fibrotic agent in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and opens the door to the evaluation of <z:chebi fb="0" ids="3962">curcumin</z:chebi> therapeutic effects in liver conditions of different aetiology and in other disorders linked to the impairment of PPARγ activity, such as <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>LINKED ARTICLE: This article is a commentary on Lin et al., pp </plain></SENT>
<SENT sid="6" pm="."><plain>2212-2227 of this issue </plain></SENT>
<SENT sid="7" pm="."><plain>To view this paper visit http://dx.doi.org/10.1111/j.1476-5381.2012.01910.x </plain></SENT>
</text></document>